Skip to main content
Sister Publication Links
  • ESG: THE IMPLEMENTATION IMPERATIVE
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Digital Health
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Unwell in America
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Opinion
April 16, 2021 10:54 AM

It's time we fulfill the ACA's promise to broaden access to lower-cost drugs

Meaghan Smith
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Meaghan Smith is executive director of the Biosimilars Forum. She previously served as a senior adviser and communications director at HHS during the Obama administration.

    The Affordable Care Act ushered in one of the greatest increases in healthcare coverage in U.S. history. Eleven years later, thanks to President Joe Biden and the sweeping pandemic relief bill, we finally have the first real expansion of the law's insurance coverage and Medicaid expansion. Despite this, we haven't realized the ACA's full potential when it comes to lowering drug costs.

    When I worked at HHS during the Obama administration, helping to implement the ACA, I met workers and families across the country deeply proud and relieved to finally have health coverage for the first time. Now, despite more than 70 congressional attempts to repeal the ACA and three visits to the Supreme Court, it is clear that the law provides necessary protections for Americans and is woven into the fabric of our society. While the ACA is most heralded for its expansion of access to affordable, quality healthcare, it also contained important provisions to lower drug costs.

    And despite the law's progress, some of the same families who finally have access to health insurance do not have access to the affordable drugs they need. One of the lesser-realized components of the ACA, the Biologics Price Competition and Innovation Act, paved the way for the Food and Drug Administration to approve biosimilars, generic-like alternatives to expensive biologics.

    It's no secret that many Americans are frustrated by rising healthcare costs, with 8 in 10 saying it's very important that Congress work on lowering prescription drug costs.

    Biologics are made from complex molecules, differing from small molecule chemically compounded drugs (like ibuprofen) in that they are manufactured in living cells. Biologics are powerful and lifesaving medications that have revolutionized the industry and changed the treatment of diseases, including certain cancers, multiple sclerosis, rheumatoid arthritis and psoriasis, to name a few.

    These treatments have transformed the lives of patients globally and are predicted to become more important than ever in the coming years, but they are accompanied by a steep price tag. In fact, biologics are the single largest driver of prescription drug spending—making up 40% of all drug spending but accounting for just 2% of prescriptions filled.

    By definition, biosimilars are biological products that are highly similar to and have no clinically meaningful difference from an existing FDA-approved reference product (brand-name biologic). This means they provide the same safe and effective treatment, but at an average of one-third less the price.

    In the years since the ACA was passed, the FDA has approved 29 biosimilar products and 20 have launched in the U.S. While this is significant, the full potential of these savings for patients and for taxpayers is far from being realized and more must be done.

    The first biosimilar became available to patients in the U.S. in 2015, and so far they have saved Americans $4.5 billion. But savings many times greater can be achieved with a stronger market. Let's compare this to the generics market as an example. Generics have saved patients trillions since they were developed and marketed. Initially sowed by doubt, it took the passage of legislation (the Hatch-Waxman Act in 1984) to boost the market.

    And while direct cost savings are a primary advantage, increased therapy adherence and compliance are associated benefits of generic use. Biosimilars are poised to save patients $100 billion by 2024, but that is only if their use increases. This is a dynamic and emerging market in the U.S. To make sure patients, employers and taxpayers receive the billions in lower drug costs that were a promise of the ACA, we need real policies to support patients' full access to these lower-cost alternatives.

    Through the American Rescue Plan, millions of Americans will be eligible to receive affordable healthcare and others' premiums will drop by thousands of dollars. This is encouraging, but President Biden and policymakers can do more to fulfill the ACA's full promise to lower drug costs. As the next generation of generics, biosimilars are the solution to how we can tackle the biggest driver of drug spending and lower healthcare costs for Americans. We just need to support them.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    MOSAIC MEDICAL bus
    New law aims to boost funding for mobile health clinics
    The Check Up: Alice Zheng, RH Capital
    The Check Up: Alice Zheng, RH Capital
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Digital Health
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Unwell in America
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing